Table 1 Clinical and laboratory features of the 60 patients with CMPD
CharacteristicEssential thrombocythaemiaPrimary myelofibrosis
No. of patients3030 (4 PMF0, 21 PMF1, 5 PMF2)
    Male1013
    Female2017
Median age (range) at diagnosis, years53 (38–82)57 (43–79)
Median Hb (range), g/dl13.4 (12–15.1)12.2 (7–16)
Median RBC count (range), ×109/l4850 (4290–6970)4100 (1850–5560)
Median WBC count (range), ×109/l8.4 (4.9–15.8)8.55 (4.0–15.3)
Median PTL count (range), ×109/l837 (401–1334)757 (505–1051)
Splenomegaly (>15 cm), n (%)6 (20)9 (30)
Treated patients, n (%)
    Hydroxyurea27 (90)25 (83)
    Antiplatelets24 (80)10 (33)
Risk factors, n (%)12 ( 40)21 (80)
Pathological events, n (%)8 (26)10 (33)
  • CMPD, chronic myeloproliferative disorder; Hb, haemoglobin; PLT, platelet; RBC, red blood cell; WBC, white blood cell.